Sales of the company’s copycat to J&J’s blockbuster medicine reached $150 million in the first quarter, adding to a surge in ...

Merck has initiated construction of a $1 billion, 470,000-square-foot biologics center of excellence in Wilmington, Delaware.

Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, ...

Summit Therapeutics' ivonescimab performed well in a phase 3 study. The cancer drug candidate is licensed from a Chinese ...

Here are five cases of companies tied up in device and drug patent litigation since the beginning of 2025: 1. NuVasive infringed five patents from a spine surgeon, a jury determined in April. The jury ...

Summit Therapeutics SMMT reported first-quarter 2025 loss per share of 9 cents, narrower than the Zacks Consensus Estimate of a loss of 10 cents. In the year-ago period, the company incurred a loss of ...

We recently published Jim Cramer’s Surprised About US Travel As He Discusses These 18 Stocks. In this article, we are going ...

Q1 2025 Earnings Call Transcript May 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.52, expectations ...

Merck & Co’s immuno-oncology drug Keytruda (pembrolizumab) is projected to be the best-selling drug by annual revenue in 2023, earning $22.2 billion by 2025, according to new research by GlobalData.

Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines.

As multiple large drugmakers look to navigate trade turbulence by pumping billions of dollars into their U.S. | Eli Lilly CEO ...

There’s a new biotech on the scene after MoonLake Immunotherapeutics launched on a mission to develop sonelokimab, a potential inflammatory diseases drug in-licensed from Germany’s Merck KGaA.